CAT panel questions GSK counsel on by-object restrictions
A lawyer acting for GlaxoSmithKline today argued that the company’s patent settlements with two generic drugmakers cannot be painted as by-object restrictions of competition – but faced questions on his approach by members of the Competition Appeal Tribunal.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.